SEMGX
Nootropic peptide for cognitive enhancement.
SEMGX
Background
SEMGX is a research analog related to Semax, a synthetic peptide based on a fragment (residues 4-10) of adrenocorticotropic hormone modified for metabolic stability. The Semax family has been studied for neuroprotective and nootropic effects, with proposed mechanisms including regulation of BDNF and its receptor TrkB and modulation of monoaminergic signaling.
The research literature, largely Russian in origin, includes rodent models of cerebral ischemia and cognition. Evidence remains predominantly preclinical.
Selected literature
- Dolotov OV, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006;1117(1):54-60.
- Medvedeva EV, et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain. Molecular Biology. 2014;48(3):373-382.
- Ashmarin IP, et al. Semax in the prevention of disease and the maintenance of working capacity. Voprosy Meditsinskoi Khimii. 1997;43(5):331-337.
References are provided for scientific context only. Citation does not imply endorsement of any use, nor a claim of safety or efficacy. Findings frequently derive from in-vitro or animal models.
Trademarks & attribution
SEMGX is a research analog related to Semax, which was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It has no registered Western pharmaceutical trademark or approved drug product. Catalyst Research Labs is not affiliated with that institute. Supplied as reference material only.
